chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID 19; COVID 19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 30Jan2021 at 13:00 as dose 2, single (Lot number: EL8982) at the age of 64 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Treatment of COVID-19; (Sep2022) Negative, notes: positive test result, after a negative test, after taking PAXLOVID; (Sep2022) Positive, notes: positive test result, after a negative test, after taking PAXLOVID. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: The patient did not receive any other medication in 2 weeks. The patient received Paxlovid from 08Sep2022 to 13Sep2022 for the Treatment of COVID-19. Rebound symptoms and positive test result after a negative test, after taking PAXLOVID. The patient did not have an any allergies.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: arm pain that has been with her since that injection; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 95-year-old female patient received BNT162b2 (BNT162B2), on 01Jun2022 as dose 2, single (Batch/Lot number: unknown), in arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for Covid-19 immunization. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 01Jun2022, outcome "unknown", described as "arm pain that has been with her since that injection". Additional information: the patient received 2nd dose of primary series on 01Jun2022. She was complaining of arm pain that has been with her since that injection. She would like to know if this is normal and expected for this pain to be there this long after. Caller thought it was "peculiar" when she received the shot and the person who gave the shot. Caller noted that her arm had bothered since getting shot. The vaccine was given "between elbow and shoulder." It was reported "When I felt it it felt like she had stuck it down too far, because I felt it. The others I did not feel. She was acting peculiar. when she put the needle in the container and she picked it up with her 2 fingers and dropped it." After a Second Shot or a Booster Shot Side effects after the second shot may be more intense than the ones experienced after the first shot. These side effects are normal signs that the body is building protection and should go away within a few days.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Blood blister, Blood pressure measurement, Rash, Skin discomfort
Clinical narrative: red raised fluid filled blister, felt damp to the touch.; remaining circle mark; felt damp to the touch; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07May2022 as dose 4 (booster), single (Lot number: FP4554), in left arm for covid-19 immunisation. The patient's relevant medical history included: "high blood pressure" (unspecified if ongoing); "type 2 diabetes" (unspecified if ongoing). Concomitant medication(s) included: AMLODIPINE; ENALAPRIL MALEATE; METFORMIN; MULTI VIT. Vaccination history included: Covid-19 vaccine (Primary immunization complete, Manufacturer Unknown), for Covid-19 immunization; Covid-19 vaccine (Dose 3, Manufacturer Unknown), for Covid-19 immunization. The following information was reported: SKIN DISCOMFORT (non-serious) with onset 08May2022, outcome "recovered", described as "felt damp to the touch"; BLOOD BLISTER (non-serious) with onset 08May2022, outcome "recovered", described as "red raised fluid filled blister, felt damp to the touch."; RASH (non-serious) with onset 08May2022, outcome "recovered", described as "remaining circle mark". The events "red raised fluid filled blister, felt damp to the touch.", "remaining circle mark" and "felt damp to the touch" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of blood blister, rash, skin discomfort.  Additional information: Red raised fluid filled blister, felt damp to the touch. Lasted close to 2 weeks. Remaining circle mark lasted over 4 weeks. No other vaccine in four weeks. No covid prior vaccination and also no covid tested post vaccination.  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Lymphadenopathy, Pain, Vaccination site erythema
Clinical narrative: Headache; body aches; fatigue; swelling and redness at injection site; swelling and redness at injection site; swollen lymph nodes; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Sep2022 at 15:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 40 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTUERER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2; MANUFACTUERER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTUERER UNKNOWN), for COVID-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering"; PAIN (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering", described as "body aches"; FATIGUE (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering"; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset 17Sep2022 at 03:00, outcome "recovering" and all described as "swelling and redness at injection site"; LYMPHADENOPATHY (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering", described as "swollen lymph nodes". Therapeutic measures were not taken as a result of headache, pain, fatigue, vaccination site swelling, vaccination site erythema, lymphadenopathy.  Additional information: Patient did not take other vaccine in four weeks and not had other medications in two weeks. Patient did not had covid prior vaccination and not tested covid post vaccination. Known allergies: No. Other medical history: No.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: Headache; body aches; fatigue; swelling and redness at injection site; swelling and redness at injection site; swollen lymph nodes; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Sep2022 at 15:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 40 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTUERER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2; MANUFACTUERER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTUERER UNKNOWN), for COVID-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering"; PAIN (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering", described as "body aches"; FATIGUE (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering"; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset 17Sep2022 at 03:00, outcome "recovering" and all described as "swelling and redness at injection site"; LYMPHADENOPATHY (non-serious) with onset 17Sep2022 at 03:00, outcome "recovering", described as "swollen lymph nodes". Therapeutic measures were not taken as a result of headache, pain, fatigue, vaccination site swelling, vaccination site erythema, lymphadenopathy.  Additional information: Patient did not take other vaccine in four weeks and not had other medications in two weeks. Patient did not had covid prior vaccination and not tested covid post vaccination. Known allergies: No. Other medical history: No.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, FLUX
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Covid positive result; Covid positive result; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 49-year-old [non-pregnant] adult female received COVID-19 immunization at a workplace clinic with the first dose of intramuscular BNT162B2 (COMIRNATY, solution for injection; Lot EP6955 expiry information not provided) as a single dose on 18Mar2021 (at 47-years-old); a second dose of intramuscular BNT162B2 (COMIRNATY, solution for injection; Lot EP6955 expiry information not provided) as a single dose on 08Apr2021 (at 47-years-old); and a third (booster) dose of intramuscular BNT162B2 (COMIRNATY, solution for injection; Lot FH8027 expiry information not provided) as a single dose in the left arm on 15Dec2021 (at 48-years-old). The patient was also immunized with influenza vaccine (flu; unspecified formulation; batch/lot and expiry information not provided) as a single dose via unspecified route on an unspecified date (within four weeks of this vaccine). Relevant medical history included no known drug allergies, and exercise or cold induced asthma; the patient was not pregnant at the time of vaccination. The patient denied any history of COVID-19 prior to vaccination. Concomitant medications included ethinylestradiol, norgestimate (ORTHO TRI-CYCLEN). The patient reported that she had a positive Covid result via nasal swab on 09Sep2022. There was no treatment received for the event. A COVID-19 test via nasal swab was performed on 18Sep2022 and was negative. The outcome of the events was recovering.
Sex: U
Vaccine: PNC13
Symptoms: Device malfunction, Incorrect dose administered by device, Underdose
Clinical narrative: only half of the dose was able to be given; syringe malfunctioned; This is a spontaneous report received from contactable reporter(s) (Physician) and a sales representative.  A patient (no qualifiers provided) received pneumococcal 13-val conj vac (dipht CRM197 protein) (PREVNAR 13), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INCORRECT DOSE ADMINISTERED BY DEVICE (non-serious), described as "only half of the dose was able to be given"; DEVICE MALFUNCTION (non-serious), described as "syringe malfunctioned".  The reporter considered "only half of the dose was able to be given" and "syringe malfunctioned" associated to pneumococcal 13-val conj vac (dipht CRM197 protein).  Additional information: Conclusion: The complaint for ''the syringe malfunctioned y'' of Prevenar 13V Injectable was investigated. The investigation included reviewing an analysis of the complaint history for the product type. The final scope was determined to be the reported product and product type, as no lot was available. A complaint sample was not returned. No related quality issues were identified during the investigation. There is no impact on product quality, regulatory, validation, stability and patient safety. Agency concludes that the reported defect is not representative of the Pfizer withheld process quality and remains acceptable. The agency process determined that no regulatory notification was required. The reported defect could not be confirmed. No root cause or CAPA were identified as the complaint was not confirmed.  Follow-up attempts are completed. No further information is expected.  Follow-up (18Aug2022): This is a spontaneous follow-up report received from a contactable Physician via Pfizer . Updated information included reporter details, reaction data and clinical course details.  Follow-up attempts are completed. No further information is expected.  Follow-up (14Sep2022): This is a follow-up report from product quality group providing investigation results: Updated information included Product Complaint No. was added.  Follow-up attempts are completed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Pyrexia, Throat tightness
Clinical narrative: Tightness in throat; Swelling in arm; High fever; This is a spontaneous report received from contactable reporter(s) (Physician). Other Case identifier(s): (Novavax).  A female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: THROAT TIGHTNESS (non-serious), outcome "unknown", described as "Tightness in throat"; PERIPHERAL SWELLING (non-serious), outcome "unknown", described as "Swelling in arm"; PYREXIA (non-serious), outcome "unknown", described as "High fever".  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: Still diagnosed with COVID 19; Still diagnosed with COVID 19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): ID (manufacturer).  A female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 26Aug2022, outcome "unknown" and all described as "Still diagnosed with COVID 19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Immune system disorder
Clinical narrative: she has a very sensitive  immune system; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID: The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "she has a very sensitive  immune system".  Additional information: The patient got all shots from Pfizer and would like to be updated on new booster shots. If it's the Omicron vaccine same with the BA5 and where she can get it.   No Follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: PNC20
Symptoms: Injection site pain, Injection site swelling, Rash, Vaccination site pain
Clinical narrative: swelling at the injection site; Rash; burning at injection site; This is a spontaneous report received from non-contactable reporter(s) (Other HCP) from a sales representative.  A patient (no qualifiers provided) received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), as dose number unknown, single (Lot number: FX6073) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE SWELLING (non-serious), outcome "unknown", described as "swelling at the injection site"; RASH (non-serious), outcome "unknown"; VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "burning at injection site". Additional information included: there are three patients were given Prevnar 20 from the same lot number FX6073 and all three patients had the same adverse events. Rash, burning at injection site, and swelling at the injection site. No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201170676 same drug and AE, different patient;US-PFIZER INC-202201170677 same drug and AE, different patient;
Age: 8.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Error: Expired Product Administered
Age: 65.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium
Age: 70.0
Sex: F
Vaccine: COVID19-2
Symptoms: Seizure
Clinical narrative: Systemic: Seizure-Mild, Additional Details: Spouse called with report of a seizure several hours after vaccination
Age: 17.0
Sex: M
Vaccine: COVID19-2
Symptoms: Feeling hot, Flushing, Hyperhidrosis, Nausea, Pallor
Clinical narrative: Systemic: mom said he was having seizure but i didnt see it after calling 911 he was alert but pale and lips white, beaded with sweat said he was hot, nauseous, ears ringing and thirsty.-Mild, Systemic: Flushed / Sweating-Mild, Systemic: Nausea-Mild, Additional Details: his color started to come back and he was responsive and said he was no longer nauseous when paramedics got there
Age: 17.0
Sex: M
Vaccine: COVID19-2
Symptoms: Seizure, Thirst, Tinnitus
Clinical narrative: Systemic: mom said he was having seizure but i didnt see it after calling 911 he was alert but pale and lips white, beaded with sweat said he was hot, nauseous, ears ringing and thirsty.-Mild, Systemic: Flushed / Sweating-Mild, Systemic: Nausea-Mild, Additional Details: his color started to come back and he was responsive and said he was no longer nauseous when paramedics got there
Age: 82.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injected limb mobility decreased, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Site: Pain at Injection Site-Mild, Site: Swelling at Injection Site-Medium, Additional Details: Patient reported her arm was still somewhat swollen and warm to touch at injection site.  She still had mobility of the arm and wasn't restricted in movement.  She was more concerned about efficacy of the vaccine since she doesn't usually get those effects locally.
Age: 85.0
Sex: F
Vaccine: COVID19-2
Symptoms: Extra dose administered, Injection site bruising, Injection site pruritus, Pruritus
Clinical narrative: Site: Bruising at Injection Site-Medium, Site: Itching at Injection Site-Medium, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Additional Details: patient showed up on Saturday 09/17 with bruised and itchy left arm right starting the spot of injection till the whole left hand.
Age: 58.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pain, Injection site swelling, Pain in extremity, Peripheral swelling
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details:  THEN PATIENT'S DAUGHTER CALLED A WEEK AFTER THE INJECTION AND SAID THAT PATIENT'S ARM IS SWOLLEN AND PAINFUL. ADVISED PATIENT TO DO WARM COMPRESS TO PROMOTE BLOOD CIRCULATION.PATINET ADVISED TO GO TO MD IF NOT RESOLVED
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  dose 1 Pfizer 1/27/21 EL0142 dose 2 Pfizer 2/18/21 EM9810
Age: 68.0
Sex: F
Vaccine: FLUA4
Symptoms: Extra dose administered
Clinical narrative: pt was accidentally given this flu vaccine twice, once in each arm
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  dose 1 Pfizer 2/5/21 EL9269 dose 2 Pfizer 2/26/21 EN6198
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect product formulation administered
Clinical narrative: Question 5:   Client contacted and no adverse event to client has occurred at this time.                        Moderna monovalent booster dose was given prior to receiving information to stop giving.
Age: 71.0
Sex: F
Vaccine: COVID19, VARZOS
Symptoms: Incorrect product formulation administered
Clinical narrative: Question 5:  Moderna monovalent booster administered prior to receiving information to stop giving as boosters.  Client contacted and no adverse signs/ symptoms have occurred as of this time.
Age: 75.0
Sex: M
Vaccine: COVID19, VARZOS
Symptoms: Incorrect product formulation administered
Clinical narrative: Question 5: Moderna monovalent booster administered prior to receiving information to stop giving. Client contacted and no adverse signs or symptoms have occurred as of this time.
Age: 44.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site bruising, Injection site discolouration, Injection site nodule, Injection site pain, Pain
Clinical narrative: Moderate R arm pain within 3 hours of injection. I found a blueish bruise when the bandaid was removed.   6 hours after vaccine:  there was a hard knot at the injection site with dark purple bruising approx 2? area on upper arm.  16 hours after vaccine:  my arm hurts regardless of activity. Arm pain is radiating down to my elbow and occasionally into my R hand.
Age: 44.0
Sex: F
Vaccine: FLU4
Symptoms: Pain in extremity
Clinical narrative: Moderate R arm pain within 3 hours of injection. I found a blueish bruise when the bandaid was removed.   6 hours after vaccine:  there was a hard knot at the injection site with dark purple bruising approx 2? area on upper arm.  16 hours after vaccine:  my arm hurts regardless of activity. Arm pain is radiating down to my elbow and occasionally into my R hand.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Adverse drug reaction, Arthralgia, Bedridden, Blood test, Electroencephalogram
Clinical narrative: The first few days were the 'typical' side effects I was advised of.    They did not get better.  I had crippling joint pain in my nerves on and off for three weeks.  I slowly lost my ability to walk.  Sometime I was able to shuffle around (like a 95 year old person) .  On 1/10/2022 finally I was bed ridden and had to be carried to the bathroom as I could not get my legs to work.   Then on 1/11/2022 I woke up with SHINGLES!  By late January I was able to walk and function normally.  Then on 3/22/2022 I was knocked out for endoscopy.  My joint pain and inabailty to walk then returned along with 'episodes'  During an episode,  my mind  functions fine but I am unable to make my body work.  I lose the ability to walk, I fall down, speech is slow, I breath through my mouth and it looks like I'm having a stroke.  I've been to two neurologists and had  two MRI's, spinal taps, blood work plus many other tests but I have not had any strokes or seizures or anything else.  From March through August I would have 1-3 episodes a day.  Some episodes were very severe, some were mild.  I was unable to drive for six months or do any kind of activity.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Electromyogram, Endoscopy, Fall, Gait disturbance, Gait inability
Clinical narrative: The first few days were the 'typical' side effects I was advised of.    They did not get better.  I had crippling joint pain in my nerves on and off for three weeks.  I slowly lost my ability to walk.  Sometime I was able to shuffle around (like a 95 year old person) .  On 1/10/2022 finally I was bed ridden and had to be carried to the bathroom as I could not get my legs to work.   Then on 1/11/2022 I woke up with SHINGLES!  By late January I was able to walk and function normally.  Then on 3/22/2022 I was knocked out for endoscopy.  My joint pain and inabailty to walk then returned along with 'episodes'  During an episode,  my mind  functions fine but I am unable to make my body work.  I lose the ability to walk, I fall down, speech is slow, I breath through my mouth and it looks like I'm having a stroke.  I've been to two neurologists and had  two MRI's, spinal taps, blood work plus many other tests but I have not had any strokes or seizures or anything else.  From March through August I would have 1-3 episodes a day.  Some episodes were very severe, some were mild.  I was unable to drive for six months or do any kind of activity.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: General physical condition abnormal, Herpes zoster, Impaired driving ability, Laboratory test, Loss of personal independence in daily activities
Clinical narrative: The first few days were the 'typical' side effects I was advised of.    They did not get better.  I had crippling joint pain in my nerves on and off for three weeks.  I slowly lost my ability to walk.  Sometime I was able to shuffle around (like a 95 year old person) .  On 1/10/2022 finally I was bed ridden and had to be carried to the bathroom as I could not get my legs to work.   Then on 1/11/2022 I woke up with SHINGLES!  By late January I was able to walk and function normally.  Then on 3/22/2022 I was knocked out for endoscopy.  My joint pain and inabailty to walk then returned along with 'episodes'  During an episode,  my mind  functions fine but I am unable to make my body work.  I lose the ability to walk, I fall down, speech is slow, I breath through my mouth and it looks like I'm having a stroke.  I've been to two neurologists and had  two MRI's, spinal taps, blood work plus many other tests but I have not had any strokes or seizures or anything else.  From March through August I would have 1-3 episodes a day.  Some episodes were very severe, some were mild.  I was unable to drive for six months or do any kind of activity.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Lumbar puncture, Magnetic resonance imaging, Mouth breathing, Musculoskeletal disorder, Neuralgia
Clinical narrative: The first few days were the 'typical' side effects I was advised of.    They did not get better.  I had crippling joint pain in my nerves on and off for three weeks.  I slowly lost my ability to walk.  Sometime I was able to shuffle around (like a 95 year old person) .  On 1/10/2022 finally I was bed ridden and had to be carried to the bathroom as I could not get my legs to work.   Then on 1/11/2022 I woke up with SHINGLES!  By late January I was able to walk and function normally.  Then on 3/22/2022 I was knocked out for endoscopy.  My joint pain and inabailty to walk then returned along with 'episodes'  During an episode,  my mind  functions fine but I am unable to make my body work.  I lose the ability to walk, I fall down, speech is slow, I breath through my mouth and it looks like I'm having a stroke.  I've been to two neurologists and had  two MRI's, spinal taps, blood work plus many other tests but I have not had any strokes or seizures or anything else.  From March through August I would have 1-3 episodes a day.  Some episodes were very severe, some were mild.  I was unable to drive for six months or do any kind of activity.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Scan with contrast, Slow speech
Clinical narrative: The first few days were the 'typical' side effects I was advised of.    They did not get better.  I had crippling joint pain in my nerves on and off for three weeks.  I slowly lost my ability to walk.  Sometime I was able to shuffle around (like a 95 year old person) .  On 1/10/2022 finally I was bed ridden and had to be carried to the bathroom as I could not get my legs to work.   Then on 1/11/2022 I woke up with SHINGLES!  By late January I was able to walk and function normally.  Then on 3/22/2022 I was knocked out for endoscopy.  My joint pain and inabailty to walk then returned along with 'episodes'  During an episode,  my mind  functions fine but I am unable to make my body work.  I lose the ability to walk, I fall down, speech is slow, I breath through my mouth and it looks like I'm having a stroke.  I've been to two neurologists and had  two MRI's, spinal taps, blood work plus many other tests but I have not had any strokes or seizures or anything else.  From March through August I would have 1-3 episodes a day.  Some episodes were very severe, some were mild.  I was unable to drive for six months or do any kind of activity.
Age: 73.0
Sex: M
Vaccine: FLU4
Symptoms: Abdominal pain upper, Headache
Clinical narrative: Headache and stomach pain gradually worsening
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Asthenia, COVID-19, Chest X-ray, Confusional state
Clinical narrative: The patient is a 68 y.o. female patient with history of nonalcoholic liver cirrhosis, history of gastric bypass 1998, peptic ulcer disease presented with confusion COVID-positive   Acute hypoxemic respiratory failure Covid-19 Virus Infection Date of onset of symptoms: 9/2/2022 Symptoms present on admission: Yes Date of covid positive test: 9/4/2022 Vaccination status: vaccinated Imaging: Chest x-ray Oxygen requirements on admission: Yes Current oxygen requirements: She was weaned off to room air before discharge Medical therapy: steroids and remdesivir Consultants following: ID Anticipated special isolation end date: 9/13/2022   Acute encephalopathy, likely hepatic in the setting of lactulose noncompliance and viral infection, resolved Nonalcoholic liver cirrhosis Ongoing diarrhea Lactulose 30 mg 3 times daily, she did not have a bowel movement yesterday, up titrate to 3 bowel movements a day Supportive care Pain management   History of gastric bypass   History of peptic ulcer disease Protonix IV   Urinary tract infection, ceftriaxone   Weakness and frequent falls She was provided with home health
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Constipation, Diarrhoea, Fall, Hepatic encephalopathy, SARS-CoV-2 test positive
Clinical narrative: The patient is a 68 y.o. female patient with history of nonalcoholic liver cirrhosis, history of gastric bypass 1998, peptic ulcer disease presented with confusion COVID-positive   Acute hypoxemic respiratory failure Covid-19 Virus Infection Date of onset of symptoms: 9/2/2022 Symptoms present on admission: Yes Date of covid positive test: 9/4/2022 Vaccination status: vaccinated Imaging: Chest x-ray Oxygen requirements on admission: Yes Current oxygen requirements: She was weaned off to room air before discharge Medical therapy: steroids and remdesivir Consultants following: ID Anticipated special isolation end date: 9/13/2022   Acute encephalopathy, likely hepatic in the setting of lactulose noncompliance and viral infection, resolved Nonalcoholic liver cirrhosis Ongoing diarrhea Lactulose 30 mg 3 times daily, she did not have a bowel movement yesterday, up titrate to 3 bowel movements a day Supportive care Pain management   History of gastric bypass   History of peptic ulcer disease Protonix IV   Urinary tract infection, ceftriaxone   Weakness and frequent falls She was provided with home health
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Treatment noncompliance, Urinary tract infection, Viral infection
Clinical narrative: The patient is a 68 y.o. female patient with history of nonalcoholic liver cirrhosis, history of gastric bypass 1998, peptic ulcer disease presented with confusion COVID-positive   Acute hypoxemic respiratory failure Covid-19 Virus Infection Date of onset of symptoms: 9/2/2022 Symptoms present on admission: Yes Date of covid positive test: 9/4/2022 Vaccination status: vaccinated Imaging: Chest x-ray Oxygen requirements on admission: Yes Current oxygen requirements: She was weaned off to room air before discharge Medical therapy: steroids and remdesivir Consultants following: ID Anticipated special isolation end date: 9/13/2022   Acute encephalopathy, likely hepatic in the setting of lactulose noncompliance and viral infection, resolved Nonalcoholic liver cirrhosis Ongoing diarrhea Lactulose 30 mg 3 times daily, she did not have a bowel movement yesterday, up titrate to 3 bowel movements a day Supportive care Pain management   History of gastric bypass   History of peptic ulcer disease Protonix IV   Urinary tract infection, ceftriaxone   Weakness and frequent falls She was provided with home health
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Body temperature increased, Chills, Discomfort, Fatigue
Clinical narrative: 1. Immediate intense ache in arm; fever, chills, fatigue, body aches at night; skin temperature on body was extremely high - 102.7 2. Low fever, chills, fatigue next day 3. Felt better but had a strange "blister" emerge on my hand - raised bump, blister, very itchy 4. Blisters started to emerge over the next few days all over - mostly my hands, arms & legs - very itchy and uncomfortable 5. Continued blisters
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Immediate post-injection reaction, Pain, Pain in extremity, Pruritus, Pyrexia
Clinical narrative: 1. Immediate intense ache in arm; fever, chills, fatigue, body aches at night; skin temperature on body was extremely high - 102.7 2. Low fever, chills, fatigue next day 3. Felt better but had a strange "blister" emerge on my hand - raised bump, blister, very itchy 4. Blisters started to emerge over the next few days all over - mostly my hands, arms & legs - very itchy and uncomfortable 5. Continued blisters
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Swelling
Clinical narrative: 1. Immediate intense ache in arm; fever, chills, fatigue, body aches at night; skin temperature on body was extremely high - 102.7 2. Low fever, chills, fatigue next day 3. Felt better but had a strange "blister" emerge on my hand - raised bump, blister, very itchy 4. Blisters started to emerge over the next few days all over - mostly my hands, arms & legs - very itchy and uncomfortable 5. Continued blisters
Age: 89.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Covid vaccine was administered past beyond use date
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Acute kidney injury, Blood creatinine increased, Blood sodium decreased, Blood urea increased, COVID-19
Clinical narrative: Patient is a 51 y.o. female with history of renal transplant (on immunosuppressants) and current COVID-19 infection who presented from home on 9/6/2022 with worsening dyspnea and cough, along with worsening renal function.  Nephrology and ID involved with care.  Fevers  COVID-19 pneumonia Patient overall feeling improved, symptoms are resolving.  Initially presented with worsening cough, dyspnea, fevers, diarrhea in the setting of COVID-19; tested positive 8/24 on home rapid test. Symptom onset ~8/19-8/20. CXR at COPC 9/2 suggestive of CHF, indeterminate pulmonary nodules within R lung; CXR in ED with diminished lung volumes and crowding of vasculature, faint opacity in R mid to lower lung zone; CT chest with patchy ground glass opacities likely consistent with COVID / viral pneumonitis  - pt fully vaccinated and boosted x 2; had Evushield in March 2022; could not get MAB and not a candidate for Paxlovid.  Monoclonal antibodies given during this hospitalization - TTE obtained, no evidence of overt volume overload -will continue isolation in the hospital and continue CDC guidelines in the outpatient setting.  We discussed ongoing isolation and mask wearing in the home setting given her recent fever. - ID consulted for guidance on further infectious work-up, appreciate recommendations   AKI on CKD 4 Hypovolemia, hyponatremia  History of kidney transplant History of metabolic acidosis With history of membranous nephropathy. S/p deceased donor transplant 6/1999 at OSU; functioned until 2011; then s/p cadaveric kidney transplant 3/30/2016 (second transplant); 11/30/20 transplant kidney biopsy with evidence of acute on chronic rejection with transplant glomerulopathy  - sCr 2.78 and Na 134 on admit 9/6; improved compared to COPC labs 9/2 which showed sCr 3.1, BUN 56 - baseline sCr ~2.1?2.3 - continue home immunosuppression regimen -Close to patient follow-up with her nephrologist in outpatient setting for recheck of renal function this upcoming week.   History of nonischemic CMP Elevated troponin No evidence of overt volume overload on exam.  Recovered EF; secondary to ESRD per OP notes.  Ongoing care in the outpatient setting   Hypertension  Home beta-blocker dose increased.   Pancytopenia History of anemia of CKD Hemoglobin 9.2, WBC 4.05, platelets 118 on admission 9/6. COPC labs 9/2 with Hgb 9.2, WBC 4.4, PLT 117. ESA per nephrology, started 4/2021, goal hemoglobin 10?11. Noted history of neutropenia due to higher dose Myfortic, resolved with reduction and use of steroids -Continue to follow counts in the outpatient setting  Hyperlipidemia Resume statin therapy on discharge
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Chest X-ray abnormal, Chronic kidney disease, Computerised tomogram thorax abnormal, Cough
Clinical narrative: Patient is a 51 y.o. female with history of renal transplant (on immunosuppressants) and current COVID-19 infection who presented from home on 9/6/2022 with worsening dyspnea and cough, along with worsening renal function.  Nephrology and ID involved with care.  Fevers  COVID-19 pneumonia Patient overall feeling improved, symptoms are resolving.  Initially presented with worsening cough, dyspnea, fevers, diarrhea in the setting of COVID-19; tested positive 8/24 on home rapid test. Symptom onset ~8/19-8/20. CXR at COPC 9/2 suggestive of CHF, indeterminate pulmonary nodules within R lung; CXR in ED with diminished lung volumes and crowding of vasculature, faint opacity in R mid to lower lung zone; CT chest with patchy ground glass opacities likely consistent with COVID / viral pneumonitis  - pt fully vaccinated and boosted x 2; had Evushield in March 2022; could not get MAB and not a candidate for Paxlovid.  Monoclonal antibodies given during this hospitalization - TTE obtained, no evidence of overt volume overload -will continue isolation in the hospital and continue CDC guidelines in the outpatient setting.  We discussed ongoing isolation and mask wearing in the home setting given her recent fever. - ID consulted for guidance on further infectious work-up, appreciate recommendations   AKI on CKD 4 Hypovolemia, hyponatremia  History of kidney transplant History of metabolic acidosis With history of membranous nephropathy. S/p deceased donor transplant 6/1999 at OSU; functioned until 2011; then s/p cadaveric kidney transplant 3/30/2016 (second transplant); 11/30/20 transplant kidney biopsy with evidence of acute on chronic rejection with transplant glomerulopathy  - sCr 2.78 and Na 134 on admit 9/6; improved compared to COPC labs 9/2 which showed sCr 3.1, BUN 56 - baseline sCr ~2.1?2.3 - continue home immunosuppression regimen -Close to patient follow-up with her nephrologist in outpatient setting for recheck of renal function this upcoming week.   History of nonischemic CMP Elevated troponin No evidence of overt volume overload on exam.  Recovered EF; secondary to ESRD per OP notes.  Ongoing care in the outpatient setting   Hypertension  Home beta-blocker dose increased.   Pancytopenia History of anemia of CKD Hemoglobin 9.2, WBC 4.05, platelets 118 on admission 9/6. COPC labs 9/2 with Hgb 9.2, WBC 4.4, PLT 117. ESA per nephrology, started 4/2021, goal hemoglobin 10?11. Noted history of neutropenia due to higher dose Myfortic, resolved with reduction and use of steroids -Continue to follow counts in the outpatient setting  Hyperlipidemia Resume statin therapy on discharge
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dyspnoea, Echocardiogram normal, End stage renal disease, Haemoglobin decreased
Clinical narrative: Patient is a 51 y.o. female with history of renal transplant (on immunosuppressants) and current COVID-19 infection who presented from home on 9/6/2022 with worsening dyspnea and cough, along with worsening renal function.  Nephrology and ID involved with care.  Fevers  COVID-19 pneumonia Patient overall feeling improved, symptoms are resolving.  Initially presented with worsening cough, dyspnea, fevers, diarrhea in the setting of COVID-19; tested positive 8/24 on home rapid test. Symptom onset ~8/19-8/20. CXR at COPC 9/2 suggestive of CHF, indeterminate pulmonary nodules within R lung; CXR in ED with diminished lung volumes and crowding of vasculature, faint opacity in R mid to lower lung zone; CT chest with patchy ground glass opacities likely consistent with COVID / viral pneumonitis  - pt fully vaccinated and boosted x 2; had Evushield in March 2022; could not get MAB and not a candidate for Paxlovid.  Monoclonal antibodies given during this hospitalization - TTE obtained, no evidence of overt volume overload -will continue isolation in the hospital and continue CDC guidelines in the outpatient setting.  We discussed ongoing isolation and mask wearing in the home setting given her recent fever. - ID consulted for guidance on further infectious work-up, appreciate recommendations   AKI on CKD 4 Hypovolemia, hyponatremia  History of kidney transplant History of metabolic acidosis With history of membranous nephropathy. S/p deceased donor transplant 6/1999 at OSU; functioned until 2011; then s/p cadaveric kidney transplant 3/30/2016 (second transplant); 11/30/20 transplant kidney biopsy with evidence of acute on chronic rejection with transplant glomerulopathy  - sCr 2.78 and Na 134 on admit 9/6; improved compared to COPC labs 9/2 which showed sCr 3.1, BUN 56 - baseline sCr ~2.1?2.3 - continue home immunosuppression regimen -Close to patient follow-up with her nephrologist in outpatient setting for recheck of renal function this upcoming week.   History of nonischemic CMP Elevated troponin No evidence of overt volume overload on exam.  Recovered EF; secondary to ESRD per OP notes.  Ongoing care in the outpatient setting   Hypertension  Home beta-blocker dose increased.   Pancytopenia History of anemia of CKD Hemoglobin 9.2, WBC 4.05, platelets 118 on admission 9/6. COPC labs 9/2 with Hgb 9.2, WBC 4.4, PLT 117. ESA per nephrology, started 4/2021, goal hemoglobin 10?11. Noted history of neutropenia due to higher dose Myfortic, resolved with reduction and use of steroids -Continue to follow counts in the outpatient setting  Hyperlipidemia Resume statin therapy on discharge
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperlipidaemia, Hypertension, Hyponatraemia, Hypovolaemia, Immunosuppressant drug therapy
Clinical narrative: Patient is a 51 y.o. female with history of renal transplant (on immunosuppressants) and current COVID-19 infection who presented from home on 9/6/2022 with worsening dyspnea and cough, along with worsening renal function.  Nephrology and ID involved with care.  Fevers  COVID-19 pneumonia Patient overall feeling improved, symptoms are resolving.  Initially presented with worsening cough, dyspnea, fevers, diarrhea in the setting of COVID-19; tested positive 8/24 on home rapid test. Symptom onset ~8/19-8/20. CXR at COPC 9/2 suggestive of CHF, indeterminate pulmonary nodules within R lung; CXR in ED with diminished lung volumes and crowding of vasculature, faint opacity in R mid to lower lung zone; CT chest with patchy ground glass opacities likely consistent with COVID / viral pneumonitis  - pt fully vaccinated and boosted x 2; had Evushield in March 2022; could not get MAB and not a candidate for Paxlovid.  Monoclonal antibodies given during this hospitalization - TTE obtained, no evidence of overt volume overload -will continue isolation in the hospital and continue CDC guidelines in the outpatient setting.  We discussed ongoing isolation and mask wearing in the home setting given her recent fever. - ID consulted for guidance on further infectious work-up, appreciate recommendations   AKI on CKD 4 Hypovolemia, hyponatremia  History of kidney transplant History of metabolic acidosis With history of membranous nephropathy. S/p deceased donor transplant 6/1999 at OSU; functioned until 2011; then s/p cadaveric kidney transplant 3/30/2016 (second transplant); 11/30/20 transplant kidney biopsy with evidence of acute on chronic rejection with transplant glomerulopathy  - sCr 2.78 and Na 134 on admit 9/6; improved compared to COPC labs 9/2 which showed sCr 3.1, BUN 56 - baseline sCr ~2.1?2.3 - continue home immunosuppression regimen -Close to patient follow-up with her nephrologist in outpatient setting for recheck of renal function this upcoming week.   History of nonischemic CMP Elevated troponin No evidence of overt volume overload on exam.  Recovered EF; secondary to ESRD per OP notes.  Ongoing care in the outpatient setting   Hypertension  Home beta-blocker dose increased.   Pancytopenia History of anemia of CKD Hemoglobin 9.2, WBC 4.05, platelets 118 on admission 9/6. COPC labs 9/2 with Hgb 9.2, WBC 4.4, PLT 117. ESA per nephrology, started 4/2021, goal hemoglobin 10?11. Noted history of neutropenia due to higher dose Myfortic, resolved with reduction and use of steroids -Continue to follow counts in the outpatient setting  Hyperlipidemia Resume statin therapy on discharge